Orchid Pharma is setting up India’s first biotechnology fermentation-based facility for 7-Amino Cephalosporanic Acid (7-ACA) with an investment of about ₹600 crore in Kathua, Jammu & Kashmir, marking a strategic shift in the country’s antibiotics and API manufacturing landscape. The foundation stone for the Orchid Biopharma facility was laid in the presence of Dr. Jitendra Singh, Minister of State (Independent Charge) for Science and Technology, who termed the project a critical step in achieving self-reliance in key starting materials (KSMs) for essential medicines.
The plant will produce 7-ACA, a core KSM for cephalosporin antibiotics, through fermentation technology at a time when India remains dependent on imports for several critical intermediates. By localising production of this high-value KSM, Orchid’s project is expected to strengthen the domestic antibiotic supply chain, reduce foreign exchange outgo and enhance security of supply for hospitals and manufacturers.
Dr. Singh highlighted that the investment under the Production Linked Incentive (PLI) scheme signals growing confidence in Jammu & Kashmir’s industrial and innovation potential. He underlined that the project aligns closely with the Union government’s Make in India vision and the recently announced ₹10,000 crore Biopharma Shakti initiative, which seeks to build a globally competitive biotechnology and biopharma ecosystem.
The ceremony also spotlighted Orchid Pharma’s innovation track record. The company remains the only Indian pharmaceutical firm to have discovered a new chemical entity (NCE) antibiotic, now approved in major markets including the US and Europe and used in more than 20,000 patients for difficult-to-treat infections. This positions Orchid as a key Indian player in the global antimicrobial resistance (AMR) response, complementing its dedicated Orchid AMS division and ongoing stewardship collaborations with hospitals.
AMR is already recognised as a “silent pandemic”, with the World Health Organization estimating that drug-resistant infections contribute to over five million deaths worldwide each year. In India, rising resistance to beta-lactams and cephalosporins is straining hospital resources and driving up costs, making reliable access to effective antibiotics and rational use both clinical and economic priorities.
As part of the Kathua event, Orchid Pharma felicitated select physicians for their contributions in managing severe infections and announced support for treatment access programmes, offering free therapy for one patient per doctor present. Company representatives reiterated that expanding access to advanced antibiotics must go hand-in-hand with robust stewardship, surveillance and clinician education.
Stakeholders at the ceremony also discussed deeper collaboration between industry, academia and government to scale up biotechnology skill development and fermentation technology capabilities in India. Building such capacity, they noted, will be essential to sustain advanced pharmaceutical manufacturing, de-risk supply chains and ensure India can respond more effectively to future infectious disease threats.
The event concluded with a shared commitment by government, industry leaders and clinicians to accelerate domestic biopharma capability-building and support India’s broader AMR agenda, from diagnostics and stewardship to resilient antibiotic manufacturing.
